Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04241068 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
A Phase 3 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,696
- Enrollment target
NCT04241068 is a Phase 3 study that was terminated before completion, run by Biogen. The registered enrollment target is 1,696 participants.
The verdict
NCT04241068, a Phase 3 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,696 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received placebo (i.e. treatment-naïve participants).
Interventions
- DRUG Aducanumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,696 participants |
| Start Date | 2020-03-02 |
| Est. Completion | 2024-07-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04241068
The ClinicalTrials.gov registry entry for NCT04241068 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,696 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aducanumab is the first listed.
NCT04241068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04241068 about?
NCT04241068 is a clinical study titled "A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205". The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received...
What is the current status of trial NCT04241068?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,696 participants. The study started on 2020-03-02. Estimated completion is 2024-07-22.
What interventions are being tested in trial NCT04241068?
The interventions under investigation include: Aducanumab (DRUG).
Who is sponsoring clinical trial NCT04241068?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.